Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines

Vet Immunol Immunopathol. 2022 Jan:243:110367. doi: 10.1016/j.vetimm.2021.110367. Epub 2021 Dec 9.

Abstract

Urothelial carcinoma (UC) is the most common urinary tumor in dogs and despite combinational therapies, only modest improvements in survival have been achieved in recent years. Given the utility of monoclonal antibodies against PD-1 and PD-L1 in human UC, we evaluated the protein and mRNA expression in three established canine urothelial carcinoma cell lines. Flow cytometry and western blot analysis confirmed cell line expression of both molecules in varying degrees. Reverse transcription PCR (RT-PCR) documented mRNA expression in all three cell lines for both PD-1 and PD-L1. Fluorescence microscopy was consistent with strong PD-1 and PD-L1 expression in the canine cell lines and was in line with previous human literature. Importantly, the flow cytometry work described in this study revealed higher cell intrinsic PD-1 expression in these cell lines which may have implications for tumor behavior and potential treatment opportunities in the future. Further work is necessary to determine the expression patterns in canine UC and potential for benefit with immunotherapy directed against PD-1 and PD-L1.

Keywords: Cancer; Dog; Programmed death ligand 1; Programmed death receptor 1; Urothelial carcinoma.

MeSH terms

  • Animals
  • B7-H1 Antigen* / genetics
  • Carcinoma, Transitional Cell* / veterinary
  • Cell Line, Tumor
  • Dog Diseases
  • Dogs
  • Programmed Cell Death 1 Receptor / genetics*
  • RNA, Messenger
  • Urinary Bladder Neoplasms* / veterinary

Substances

  • B7-H1 Antigen
  • Programmed Cell Death 1 Receptor
  • RNA, Messenger